Simulations Plus (NASDAQ:SLP) Releases FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.070-1.200 for the period, compared to the consensus earnings per share estimate of 0.900. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.7 million. Simulations Plus also updated its FY25 guidance to $1.07-$1.20 EPS.

Simulations Plus Trading Up 4.4 %

Shares of NASDAQ SLP traded up $1.29 during trading hours on Tuesday, reaching $30.39. The stock had a trading volume of 492,972 shares, compared to its average volume of 303,448. The firm has a market cap of $610.38 million, a price-to-earnings ratio of 62.02 and a beta of 0.80. Simulations Plus has a fifty-two week low of $27.07 and a fifty-two week high of $51.22. The firm has a 50-day moving average of $29.78 and a 200-day moving average of $34.16.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The firm had revenue of $18.70 million for the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the previous year, the firm posted $0.18 EPS. The firm’s revenue for the quarter was up 19.9% on a year-over-year basis. On average, equities analysts predict that Simulations Plus will post 1.1 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on SLP. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Wednesday, November 6th. StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. BTIG Research dropped their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Finally, Stephens assumed coverage on Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Simulations Plus presently has an average rating of “Moderate Buy” and an average target price of $51.40.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the sale, the director now directly owns 3,442,584 shares in the company, valued at $109,336,467.84. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 19.40% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.